Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]

Core Viewpoint - INVO Fertility, Inc. has received a notice of allowance for a new patent on a modified version of its proprietary INVOcell device, extending intellectual property protection through 2040, which reflects feedback from embryologists to simplify the device's use [1][2][5] Company Overview - INVO Fertility is a healthcare company focused on the fertility sector, dedicated to expanding assisted reproductive technology (ART) care [6] - The company operates two INVO Centers and one IVF clinic in the United States, and engages in the sale and distribution of the INVOcell technology to third-party fertility clinics [6] Product Details - The INVOcell device is the world's first FDA-cleared intravaginal culture (IVC) system, allowing fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [3][4] - The device was originally granted FDA clearance in 2015 and received an update in 2023 to extend the incubation period from 3 days to 5 days [4] - The modified design of the INVOcell device was based on embryologists' feedback, transitioning from a dual-chamber to a singular main chamber [4] Market Position - The INVOcell procedure offers comparable pregnancy rates to traditional IVF while providing a more patient-centered and affordable experience [5][6] - The company believes that the IVC procedure can deliver similar results at a lower cost compared to traditional IVF and is more effective than intrauterine insemination (IUI) [6]

Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].

Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the America's Best Fertility Clinics included quality metrics based on ART indicators published by the CDC [5] - A nationwide online survey was conducted involving reproductive endocrinologists, infertility specialists, and other medical professionals [5] - Accreditation data from various medical organizations and patient satisfaction data from Google reviews were also considered in the evaluation [5]

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the Best Fertility Clinics included quality metrics from ART, a nationwide survey of medical professionals, accreditation data from recognized bodies, and patient satisfaction based on Google reviews [5]

Company Overview - INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to advanced reproductive treatments through the establishment, acquisition, and operation of fertility clinics and related technologies [4] - The company operates two INVO Centers and one IVF clinic in the United States, and it is engaged in the sale and distribution of its proprietary INVOcell technology to third-party fertility clinics [4] - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more natural and affordable experience compared to traditional ART treatments [4] Upcoming Events - INVO Fertility will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 4:15 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will be available for virtual one-on-one meetings throughout the event, with arrangements facilitated through Lytham Partners [3]

"Our new Nasdaq ticker symbol of 'IVF' reflects our go-forward business concentration on the fertility care market," commented Steve Shum, CEO of INVO Fertility. "This change underscores our strategic focus on building, acquiring and operating fertility clinics in the United States and our focus on innovative reproductive services and technologies. As reinforced by the U.S. President's recent executive order to reduce the cost of IVF and expand access to fertility services, we look forward to refocusing and ...